Results 41 to 50 of about 8,359 (180)

Structural Analysis of Amylin and Amyloid β Peptide Signaling in Alzheimer’s Disease

Biomolecules
Amylin and amyloid β belong to the same protein family and activate the same receptors. Amyloid β levels are elevated in Alzheimer’s disease. Recent studies have demonstrated that amylin-based peptides can reduce the symptoms of Alzheimer’s disease in ...
Longsheng Xie, Christopher Lockhart, Steven R. Bowers, Dmitri K. Klimov, Mohsin Saleet Jafri   +4 more
doaj   +1 more source

Non‐Nutritive Artificial Sweeteners Aspartame and Acesulfame‐K Ameliorate Metabolic Dysfunction‐Associated Steatotic Liver Disease in Male Ldlr−/− Mice

iNew Medicine, EarlyView.
ABSTRACT Aspartame and acesulfame‐K are commonly used non‐nutritive artificial sweeteners, but their impacts on cardiovascular disease and metabolic dysfunction‐associated fatty liver disease (MASLD) are unclear. In this study, we evaluated the impacts of aspartame and acesulfame‐K on MASLD and atherosclerosis in male Ldlr−/− mice fed an AMLN diet ...
Jingjing Xu, Xiaohua Jiang, Jianping Weng, Suowen Xu   +3 more
wiley   +1 more source

Brain Distribution and Sexually Dimorphic Expression of Amylin in Different Reproductive Stages of the Zebra Finch (Taeniopygia guttata) Suggest Roles of the Neuropeptide in Song Learning and Social Behaviour

Frontiers in Neuroscience, 2020
The expression of the recently identified neuropeptide, amylin, is restricted in rodents to the postpartum preoptic area and may play a role in the control of parental behaviours and food intake.
Gergely Zachar, Catherine Montagnese, Emese A. Fazekas, Emese A. Fazekas, Róbert G. Kemecsei, Szilvia M. Papp, Fanni Dóra, Éva Renner, András Csillag, Ákos Pogány, Arpád Dobolyi   +10 more
doaj   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Hepatocyte TrkB Acts as a Gatekeeper Against MASH‐Related Liver Fibrosis by Suppressing the TGFβ/CCL2 Axis and Macrophage Infiltration

Cell Proliferation, EarlyView.
Hepatocyte TrkB is identified as a critical gatekeeper against MASH‐related fibrosis. Mechanistically, TrkB inhibits the TGFβ/SMAD3/FOS axis to suppress CCL2 secretion, thereby blocking pathogenic macrophage recruitment and ameliorating liver fibrosis.
Yueying Chen, Jiayi Wei, Shuxuan Li, Kefan Yin, Heming Wang, Yicheng Zhao, Shuqiang Weng, Xizhong Shen, Guangqi Song, Changfeng Zhu, Qunyan Yao, Ling Dong   +11 more
wiley   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Relation between serum amylin level and epilepsy

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2020
Background Epilepsy is a neurological disorder characterized by convulsions. Identification of biological pathways underlying epilepsy and novel genes may shed light on the pathogenesis of epilepsy as well as new targets for treatment.
Necla Benlier, Gokhan Ozer, Nuri Orhan
doaj   +1 more source

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise, Eric Zijlstra, Andrea Mari, William C. Roell, Kieren J. Mather, Axel Haupt, Panagiotis Flevaris, Ran Liao, Laiyi Chua, Charles Harris, Edward J. Pratt   +10 more
wiley   +1 more source